Protea Biosciences Group Inc:製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Protea Biosciences Group Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C7571
◆発行会社(調査会社):GlobalData
◆発行日:2018年10月
◆ページ数:40
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Protea Biosciences Group Inc (Protea) is a biotechnology company that develops mass spectometry solutions. The company offers technology for identification, characterization, and quantitation of biologically-important molecules for pharmaceutical development, research, and diagnostic applications. Its products include functionalized pipette tips and plates, gel protein separation and recovery, protein sample preparation, amplus HPLC columns and mass spectrometry standards, among others. Protea’s services include bioanalytical services and mass spec imaging services. The company’s bioanalytical services include biomarker discovery, advanced proteomics and protein, biotherapeutic characterization and peptide quantitation, among others. It also provides label free imaging, translational, and drug and metabolite distribution. The company serves pharmaceutical, clinical, academic and industrial research. Protea is headquartered in Morgantown, West Virginia, the US.

Protea Biosciences Group Inc – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Protea Biosciences Group Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Protea Biosciences Group Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Protea Biosciences Group Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Protea Biosciences Group Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Protea Biosciences Group Inc, Medical Devices Deals, 2012 to YTD 2018 10
Protea Biosciences Group Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Protea Biosciences Group Inc, Pharmaceuticals & Healthcare, Deal Details 12
Partnerships 12
Protea Biosciences Enters into Co-Marketing Agreement with Proteos 12
Protea Biosciences Enters into Agreement with Agilent Technologies 13
Protea Biosciences Enters Into Research Agreement With Virginia Commonwealth University For Molecular Imaging Techniques 14
Waters Enters Into Co-Marketing Agreement With Protea Biosciences Group For LASEI DP-1000 15
Protea Biosciences Group Enters Into Co-Development Agreement With Oak Ridge National Lab 16
Licensing Agreements 17
Protea Biosciences Enters into License Agreement with George Washington University 17
Equity Offering 18
Protea Biosciences Files Registration Statement to Raise up to USD17.3 Million in Public Offering of Shares 18
Protea Biosciences Group Raises USD0.6 Million in Private Placement 19
Protea Biosciences Raises USD0.98 Million in Public Offering of Units 20
Protea Biosciences Raises USD2.53 Million in Public Offering of Units 21
Protea Biosciences Group Completes Private Placement Of Shares For US$0.7 Million 22
Protea Biosciences Completes Private Placement Of Shares For US$0.5 Million 23
Debt Offering 24
Protea Biosciences Raises USD0.1 Million in Private Placement of Debentures 24
Protea Biosciences Raises USD1.61 Million in Private Placement of Debentures 25
Protea Biosciences Raises USD2 Million in Private Placement of Debentures 26
Protea Biosciences Group Completes Private Placement Of Debt Securities For US$0.3 Million 27
Asset Transactions 28
Purdue University Acquires LAESI DP-1000 Instrument System from Protea Biosciences 28
Princeton University Acquires LAESI DP-1000 Instrument System from Protea Biosciences 29
Acquisition 30
Protea Biosciences to Acquire vivoPharm for USD11.2 Million 30
AzurRx BioPharma Acquires ProteaBio Europe for USD7 Million 32
Protea Biosciences Group Inc – Key Competitors 34
Protea Biosciences Group Inc – Key Employees 35
Protea Biosciences Group Inc – Locations And Subsidiaries 36
Head Office 36
Other Locations & Subsidiaries 36
Recent Developments 37
Financial Announcements 37
Apr 18, 2017: Protea Announces 2016 Year End Results 37
Product News 38
Jun 21, 2017: Protea introduces new molecular imaging technology 38
Other Significant Developments 39
Jul 12, 2017: Protea Announces New Test Methods for Therapeutic Antibodies 39
Appendix 40
Methodology 40
About GlobalData 40
Contact Us 40
Disclaimer 40

List of Tables
Protea Biosciences Group Inc, Pharmaceuticals & Healthcare, Key Facts 2
Protea Biosciences Group Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Protea Biosciences Group Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Protea Biosciences Group Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Protea Biosciences Group Inc, Deals By Therapy Area, 2012 to YTD 2018 9
Protea Biosciences Group Inc, Medical Devices Deals, 2012 to YTD 2018 10
Protea Biosciences Group Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Protea Biosciences Enters into Co-Marketing Agreement with Proteos 12
Protea Biosciences Enters into Agreement with Agilent Technologies 13
Protea Biosciences Enters Into Research Agreement With Virginia Commonwealth University For Molecular Imaging Techniques 14
Waters Enters Into Co-Marketing Agreement With Protea Biosciences Group For LASEI DP-1000 15
Protea Biosciences Group Enters Into Co-Development Agreement With Oak Ridge National Lab 16
Protea Biosciences Enters into License Agreement with George Washington University 17
Protea Biosciences Files Registration Statement to Raise up to USD17.3 Million in Public Offering of Shares 18
Protea Biosciences Group Raises USD0.6 Million in Private Placement 19
Protea Biosciences Raises USD0.98 Million in Public Offering of Units 20
Protea Biosciences Raises USD2.53 Million in Public Offering of Units 21
Protea Biosciences Group Completes Private Placement Of Shares For US$0.7 Million 22
Protea Biosciences Completes Private Placement Of Shares For US$0.5 Million 23
Protea Biosciences Raises USD0.1 Million in Private Placement of Debentures 24
Protea Biosciences Raises USD1.61 Million in Private Placement of Debentures 25
Protea Biosciences Raises USD2 Million in Private Placement of Debentures 26
Protea Biosciences Group Completes Private Placement Of Debt Securities For US$0.3 Million 27
Purdue University Acquires LAESI DP-1000 Instrument System from Protea Biosciences 28
Princeton University Acquires LAESI DP-1000 Instrument System from Protea Biosciences 29
Protea Biosciences to Acquire vivoPharm for USD11.2 Million 30
AzurRx BioPharma Acquires ProteaBio Europe for USD7 Million 32
Protea Biosciences Group Inc, Key Competitors 34
Protea Biosciences Group Inc, Key Employees 35
Protea Biosciences Group Inc, Subsidiaries 36

List of Figures
Protea Biosciences Group Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Protea Biosciences Group Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Protea Biosciences Group Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Protea Biosciences Group Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Protea Biosciences Group Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Protea Biosciences Group Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Protea Biosciences Group Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Protea Biosciences Group Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Protea Biosciences Group Inc, Medical Devices Deals, 2012 to YTD 2018 10

★海外企業調査レポート[Protea Biosciences Group Inc:製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Punjab & Sind Bank:企業の戦略・SWOT・財務情報
    Punjab & Sind Bank - Strategy, SWOT and Corporate Finance Report Summary Punjab & Sind Bank - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • Equinix Inc (EQIX):企業の財務・戦略的SWOT分析
    Equinix Inc (EQIX) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and th …
  • MegaChips Corp (6875):企業の財務・戦略的SWOT分析
    MegaChips Corp (6875) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • Omega Pharma NV:企業の戦略・SWOT・財務情報
    Omega Pharma NV - Strategy, SWOT and Corporate Finance Report Summary Omega Pharma NV - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpo …
  • Heron Resources Ltd:企業の戦略・SWOT・財務情報
    Heron Resources Ltd - Strategy, SWOT and Corporate Finance Report Summary Heron Resources Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • Air India Ltd.:企業の戦略・SWOT・財務分析
    Air India Ltd. - Strategy, SWOT and Corporate Finance Report Summary Air India Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpora …
  • JinkoSolar Holding Co Ltd (JKS):電力:M&Aディール及び事業提携情報
    Summary JinkoSolar Holding Co Ltd (JinkoSolar) is a manufacturer of solar products. The company is involved in manufacturing and marketing of solar power products such as silicon ingots, silicon wafers, solar modules, solar PV cells, and monocrystalline and multicrystalline photovoltaic (PV) panels. …
  • Takasago International Corporation (4914):企業の財務・戦略的SWOT分析
    Takasago International Corporation (4914) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strength …
  • Pfizer Japan Inc-製薬・医療分野:企業M&A・提携分析
    Summary Pfizer Japan Inc (Pfizer Japan), a subsidiary of Pfizer Inc is a drug company that manufactures, sells, imports and exports prescription drugs. The company’s products include axitinib, crizotinib, sunitinib malate, epirubicin hydrochloride, levofolinate calcium, clindamycin phosphate ester, …
  • Endeavor Energy Resources LP:石油・ガス:M&Aディール及び事業提携情報
    Summary Endeavor Energy Resources LP (Endeavor Energy) is an independent oil and gas company that acquires, explores, develops and produces crude oil and natural gas properties. The company has operations in the Delaware Basin which offers horizontal and vertical drilling in Winkler, Ward, Loving, R …
  • HearMeOut Ltd (HMO):企業の財務・戦略的SWOT分析
    HearMeOut Ltd (HMO) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and t …
  • 21st Century Oncology Inc:企業の戦略的SWOT分析
    21st Century Oncology Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products …
  • Taiho Pharmaceutical Co Ltd:製薬・医療:M&Aディール及び事業提携情報
    Summary Taiho Pharmaceutical Co Ltd (Taiho), a subsidiary of Otsuka Group develops and markets pharmaceutical products in the field of cancer, allergy, immunology, urology and others. Its product portfolio includes pharmaceutical products such as anti-allergic agents, anti-tumor agents, H2 receptor …
  • Analytik Jena AG:企業の戦略的SWOT分析
    Analytik Jena AG - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and servi …
  • Fischer Connectors UK:企業の戦略・SWOT・財務情報
    Fischer Connectors UK - Strategy, SWOT and Corporate Finance Report Summary Fischer Connectors UK - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • Raymond Ltd (RAYMOND EQ):企業の財務・戦略的SWOT分析
    Raymond Ltd (RAYMOND EQ) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • NextEra Energy Resources LLC:電力:M&Aディール及び事業提携情報
    Summary NextEra Energy Resources, LLC (NEER), a subsidiary of NextEra Energy, Inc., is a diversified clean energy company and is one of the largest wholesale generators of electric power in the US. The company, together with its subsidiaries owns, develops, constructs, manages and operates electrici …
  • ZAP (ZAAP):企業の財務・戦略的SWOT分析
    ZAP (ZAAP) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potent …
  • Nativis Inc-医療機器分野:企業M&A・提携分析
    Summary Nativis Inc (Nativis) is a clinical stage bio-electronics company. Its portfolio of pipeline candidates which are under development for various therapeutic areas include recurrent glioblastoma, brain metastisis, pain, rheumatoid arthritis, lung cancer and melanoma. The company’s lead product …
  • Yamada Denki Co Ltd:企業の戦略・SWOT・財務情報
    Yamada Denki Co Ltd - Strategy, SWOT and Corporate Finance Report Summary Yamada Denki Co Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆